rba-1 Antibody

Anti-Redelberger (Rba) Antibodies

Anti-Rba antibodies target the Redelberger antigen (Rba), a low-incidence blood group antigen first identified in 1974. These antibodies are clinically significant in transfusion medicine and hemolytic disease of the fetus and newborn (HDFN) diagnostics.

Research Findings:

Anti-ARRB1 (β-Arrestin-1) Antibodies

Anti-ARRB1 antibodies target β-arrestin-1, a protein involved in G-protein-coupled receptor (GPCR) signaling and immune regulation. These antibodies are used in research to study intracellular signaling pathways.

Key Applications:

• Western Blotting: Detects β-arrestin-1 (~48 kDa) in human, mouse, and rat tissues .

• Immunohistochemistry: Localizes β-arrestin-1 in cancer and immune cells .

• Functional Studies: Used to investigate β-arrestin-1’s role in receptor internalization and MAPK signaling .

Antibody Performance Data:

Research Highlights:

• Cancer Studies: β-arrestin-1 overexpression correlates with metastasis in breast and lung cancers .

• Immune Regulation: ARRB1 knockout mice show impaired T-cell receptor signaling .

Comparative Analysis

Key Challenges and Innovations

• Anti-Rba Antibodies:

  • Low prevalence of Rba+ individuals complicates reagent development .

  • Novel monoclonal anti-Rba antibodies are being explored to improve assay standardization .

• Anti-ARRB1 Antibodies:

  • Phospho-specific antibodies (e.g., Ser157) enable studies of post-translational modifications .

  • Multiplex assays integrating ARRB1 detection are advancing personalized oncology .

Future Directions

• Anti-Rba: Development of recombinant monoclonal antibodies for quality control in blood typing kits .

• Anti-ARRB1: High-throughput screening platforms to map β-arrestin-1 interactions in GPCR drug discovery .